Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.72 |
| ▸ | IKZF3 | Q9UKT9 | 16/20 | 0.72 |
| ▸ | TNF | P01375 | 5/20 | 0.67 |
| ▸ | IL1B | P01584 | 3/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107988 | 0.92 | CRBN (0.76) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL16768273 | 0.91 | CRBN (0.60) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2250317 | 0.87 | CRBN (0.80) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2250782 | 0.87 | CRBN (0.80) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2249129 | 0.87 | CRBN (0.83) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30080313 | 0.87 | CRBN (0.83) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL18975596 | 0.87 | CRBN (0.83) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2250712 | 0.86 | CRBN (0.79) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24810900 | 0.86 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2254637 | 0.86 | CRBN (0.75) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | CRBN 2429/4885IKZF3 2341/4885TNF 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.